Upstream Bio (NASDAQ:UPB) Trading 14.4% Higher – What’s Next?

Upstream Bio, Inc. (NASDAQ:UPB)’s share price was up 14.4% during trading on Wednesday . The company traded as high as $9.35 and last traded at $9.29. Approximately 732,969 shares changed hands during mid-day trading, a decline of 47% from the average daily volume of 1,395,897 shares. The stock had previously closed at $8.12.

Wall Street Analysts Forecast Growth

UPB has been the topic of a number of recent analyst reports. Evercore initiated coverage on shares of Upstream Bio in a research note on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price target on the stock. Mizuho upgraded shares of Upstream Bio to a “strong-buy” rating in a research note on Thursday, December 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a report on Wednesday, January 21st. Finally, Lifesci Capital initiated coverage on shares of Upstream Bio in a research report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Upstream Bio presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.25.

Upstream Bio Stock Performance

The company has a 50-day moving average of $20.41 and a 200-day moving average of $22.05. The stock has a market capitalization of $498.79 million, a price-to-earnings ratio of -4.91 and a beta of 2.96.

Institutional Trading of Upstream Bio

Institutional investors and hedge funds have recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new stake in Upstream Bio during the 4th quarter worth about $29,000. Torren Management LLC purchased a new position in Upstream Bio in the 4th quarter valued at about $30,000. Empowered Funds LLC purchased a new position in Upstream Bio in the 4th quarter valued at about $45,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Upstream Bio during the 4th quarter worth about $71,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Upstream Bio by 1,963.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock worth $57,000 after purchasing an additional 2,887 shares during the last quarter.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.